[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,197,378
  • Shares Outstanding, K 92,993
  • Annual Sales, $ 490,730 K
  • Annual Income, $ -25,550 K
  • EBIT $ -57 M
  • EBITDA $ 1 M
  • 60-Month Beta 1.10
  • Price/Sales 10.85
  • Price/Cash Flow 158.17
  • Price/Book 53.59

Options Overview Details

View History
  • Implied Volatility 70.63% (+1.42%)
  • Historical Volatility 27.21%
  • IV Percentile 65%
  • IV Rank 16.87%
  • IV High 220.62% on 03/19/26
  • IV Low 40.19% on 05/05/26
  • Expected Move (DTE 20) 4.59 (8.21%)
  • Put/Call Vol Ratio 0.99
  • Today's Volume 2,021
  • Volume Avg (30-Day) 547
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 30,273
  • Open Int (30-Day) 28,683
  • Expected Range 51.30 to 60.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 4
  • High Estimate $0.05
  • Low Estimate $-0.37
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.00 +5.45%
on 07/17/26
60.00 -6.85%
on 07/23/26
-0.92 (-1.62%)
since 06/30/26
3-Month
41.32 +35.26%
on 05/19/26
60.10 -7.00%
on 06/25/26
+13.77 (+32.69%)
since 04/30/26
52-Week
15.03 +271.86%
on 08/01/25
60.10 -7.00%
on 06/25/26
+40.41 (+261.05%)
since 07/30/25

Most Recent Stories

More News
Travere Therapeutics to Report Second Quarter 2026 Financial Results

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company will...

TVTX : 55.89 (-2.43%)
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

NEW YORK , July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ:...

TVTX : 55.89 (-2.43%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares...

TVTX : 55.89 (-2.43%)
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

TVTX : 55.89 (-2.43%)
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

William Rote, Ph.D., chief research officer plans to retire in early 2027 Jula Inrig, M.D., to be named executive vice president, head of research and development and...

TVTX : 55.89 (-2.43%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of...

TVTX : 55.89 (-2.43%)
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds...

TVTX : 55.89 (-2.43%)
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

TVTX : 55.89 (-2.43%)
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases ...

TVTX : 55.89 (-2.43%)
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled “Biphenyl...

TVTX : 55.89 (-2.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 59.44
2nd Resistance Point 58.49
1st Resistance Point 57.19
Last Price 55.89
1st Support Level 54.95
2nd Support Level 54.00
3rd Support Level 52.70

See More

52-Week High 60.10
Last Price 55.89
Fibonacci 61.8% 42.88
Fibonacci 50% 37.56
Fibonacci 38.2% 32.25
52-Week Low 15.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.